Home › NDC Lookup › Ingredients › Imatinib Mesylate › 00093-7629-98
⚪image loading
(from DailyMed)

Imatinib Mesylate 100 mg Tablet, Film Coated, 90-count — NDC 0093-7629-98 (Billing 00093-7629-98)

by Teva Pharmaceuticals USA, Inc. · 90 TABLET, FILM COATED in 1 BOTTLE

This is a package of 90 tablets of Imatinib Mesylate 100 mg Tablet, Film Coated from Teva Pharmaceuticals USA, Inc., marketed since Aug 2016 and currently FDA-listed; retail pharmacies pay about $0.6244 per tablet (NADAC). It is this product's only package size.

NDC 00093-7629-98
🏷️ FDA NDC (as labeled) 0093-7629-98 billing pads the labeler segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0093-7629-98 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0093 labeler · 7629 product · 98 package
Package marketed since
Aug 4, 2016
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
90 EA per package
Barcode (UPC-A, from the NDC)
3 0093762998 6
Medicaid fills, this package
326 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0093-7629-98
Product NDC 0093-7629
11-digit billing NDC 00093762998
NCPDP billing unit EA — each (per item)
Application # ANDA204285
SPL Set ID 5c0d390b-c369-4ab3-9cad-38218846adc5
Established class (EPC) Kinase Inhibitor
Mechanism of action Bcr-Abl Tyrosine Kinase Inhibitors; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A4 Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2016-08-04
Route ORAL
Dosage form TABLET, FILM COATED
Substance IMATINIB MESYLATE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 052712
GCN 19908
HICL code 022096
Ingredient (HICL) Imatinib Mesylate
HIC1 code V
Therapeutic class — broad (HIC1) Neoplasms
HIC2 code V1
Therapeutic class — intermediate (HIC2) Antineoplastic Drugs
HIC3 code V1Q
Therapeutic class — specific (HIC3) Antineoplastic Systemic Enzyme Inhibitors
AHFS code 10:00.00.00
AHFS class Antineoplastic Agents
FDB label name IMATINIB MESYLATE 100 MG TAB
FDB brand name Imatinib Mesylate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 052712
  • GCN: 19908
  • HICL (First Databank): 022096
  • AHFS class code: 10:00.00.00
Why two NDCs? The FDA registers this code as 0093-7629-98 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00093-7629-98. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name IMATINIB MESYLATE 100 MG TAB Ingredient Imatinib Mesylate
📖 What it is MedlinePlus · NLM

Imatinib is used to treat: certain types of leukemia(cancer that begins in the white blood cells) and other cancers and disorders of the blood cells certain types of gastrointestinal stromal tumors (GIST; a type of tumor that grows in the walls of the digestive passages and may spread to other parts of the body) certain types of dermatofibrosarcoma protuberans (a tumor that forms under the top layer of skin) Imatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein in cancer cells. This helps slow or stop the spread of cancer cel...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Imatinib targets specific proteins that are driving your cancer cells to grow out of control. In leukemias like CML, it blocks a faulty protein called BCR-ABL that results from a g...
  • What exactly is imatinib treating in my body?
  • Yes — always take imatinib with a meal and a large glass of water. Taking it on an empty stomach increases the chance of nausea and stomach irritation. If you're taking the tablet...
  • Does it matter when I take it or whether I eat first?
📖 Read our full Imatinib guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.624 $56.20 / 90 tablets
Medicaid paysCMS SDUD · 12 mo $0.9676 $87.08 / 90 tablets
Medicare drug plans payPart D · Q2 2026 $8.00 $720.30 / 90 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jun 2022 Jan 2026 May 2026 Sep 2026 $0.874 $0.609
▼ Down 23% over the last 12 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00093-7629-98 You're viewing this Main listing 90 TABLET, FILM COATED in 1 BOTTLE 2016-08-04 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Imatinib mesylate 100 mg 72485-0202-90 Armas 90 tablets $0.609 AB FDA listed save 2%
imatinib mesylate 100 mg 72819-0185-09 Archis 90 tablets $0.611 AB Availability likely save 2%
Imatinib Mesylate 100 mgthis 00093-7629-98 Teva 90 tablets $0.624 AB Availability likely —
Imatinib Mesylate 100 mg 00378-2245-77 Mylan 90 tablets $0.624 AB Availability likely —
imatinib mesylate 100 mg 00832-0532-09 Upsher-Smith 90 tablets $0.624 AB Availability likely —
Imatinib Mesylate 100 mg 00904-6901-04 Major 1 tablet $0.624 AB Availability likely —
Imatinib Mesylate 100 mg 31722-0296-90 Camber 90 tablets $0.624 AB Availability likely —
Imatinib Mesylate 100 mg 42292-0043-03 Mylan 1 tablet $0.624 AB Availability likely —
Imatinib Mesylate 100 mg 59651-0240-90 Aurobindo 90 tablets $0.624 AB Availability likely —
Imatinib Mesylate 100 mg 60687-0882-21 American 1 tablet $0.624 AB Availability likely —
Imatinib Mesylate 100 mg 62135-0658-90 Chartwell 90 tablets $0.624 AB Availability likely —
Imatinib Mesylate 100 mg 68001-0622-05 BluePoint 90 tablets $0.624 AB Availability likely —
Imatinib Mesylate 100 mg 82009-0086-90 QUALLENT 90 tablets $0.624 AB Availability likely —
Imatinib Mesylate 100 mg 82249-0020-90 Civica 90 tablets $0.624 AB Availability likely —
imatinib mesylate 100 mg 68001-0490-05 BluePoint 90 tablets $0.852 — FDA listed +37%
Gleevec 100 mg 00078-0401-34 Novartis 90 tablets — AB FDA listed —
Imatinib 100 mg 43598-0344-10 Dr.Reddy's 1000 tablets — AB Discontinued —
imatinib mesylate 100 mg 47335-0472-13 Sun 500 tablets — — FDA listed —
Imatinib Mesylate 100 mg 48433-0049-03 Safecor 1 tablet — AB FDA listed —
Imatinib Mesylate 100 mg 51407-0269-90 Golden 90 tablets — AB FDA listed —
Imatinib Mesylate 100 mg 60505-2900-00 Apotex 10 tablets — AB FDA listed —
imatinib mesylate 100 mg 67184-0532-01 Qilu 90 tablets — AB FDA listed —
Imatinib mesylate 100 mg 67877-0633-90 Ascend 90 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2016
On the market since
Aug 2016
📍
2026
Currently FDA-listed
10 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Imatinib inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerTeva Pharmaceuticals USA, Inc.
Application holderTEVA PHARMACEUTICALS USA
FDA applicationANDA204285 (ANDA)
Labeler code00093
First marketedAug 2016
Product typeHuman Prescription Drug
Portfolio504 products on file

More NDCs from Teva Pharmaceuticals USA, Inc. labeler code 00093

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
326
Units reimbursed last 4 qtrs
25K
Gross reimbursed last 4 qtrs
$24.2K
Avg / prescription
$74.18
Avg / unit
$0.9676
Latest quarter Q1 2026
97Rx
Medicaid pays / ea
$0.9676
gross reimbursed
vs
NADAC / ea
$0.6244
acquisition cost
=
Spread
+$0.3432
+55% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
83% FFS 17% MCO
Fee-for-service · 271 Rx Managed care · 55 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: 900 units · 15.2 per 100k residents WI Michigan: 4,724 units · 47.1 per 100k residents MI New York: 7,138 units · 36.5 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 900 units · 7.6 per 100k residents OH Pennsylvania: 1,830 units · 14.1 per 100k residents PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 8,831 units · 22.7 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 671 units · 6.2 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
6.247.1
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Michigan 47.1 /100k
2 New York 36.5 /100k
3 California 22.7 /100k
4 Wisconsin 15.2 /100k
5 Pennsylvania 14.1 /100k
6 Ohio 7.6 /100k
7 North Carolina 6.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Imatinib Mesylate — the program that covers self-administered drugs. 13 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Imatinib Mesylate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$24.35M
Claims incl. refills
31.7K
Beneficiaries
13.1K
Spend / beneficiary
$1,863.70
Spend / claim
$767.32
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 00093-7620-56 · Teva 00093-7630-56 · Teva →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.